ArticleEuropean journal of pediatrics2025
Impact of pertussis vaccination on PT-IgG levels and clinical characteristics in 3-12-month-old infants with acute pertussis.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Although some studies have explored changes in PT-IgG levels following vaccination or Bordetella pertussis infection, the relationship between PT-IgG levels and clinical characteristics in patients with acute-phase pertussis remains unclear. We retrospectively analyzed clinical data from 333 infants aged 3-12 months hospitalized with acute pertussis at the Children's Hospital of Chongqing Medical University between April 1, 2018, and July 31, 2019. Patients were stratified into vaccinated and unvaccinated groups based on their immunization records. We evaluated differences in clinical manifestations, complications, laboratory findings, and dynamics of PT-IgG antibody. The median age of disease onset was 137.5 days for unvaccinated patients and 163 days for vaccinated patients. PT-IgG levels were significantly higher in the vaccinated group (19.25 [1.58, 59.18] IU/mL) compared to the unvaccinated group (2.43 [0.05, 24.01] IU/mL; P < 0.001). Unvaccinated patients exhibited higher incidences of peak white blood cell (WBC) counts in the range of 20-30 × 10⁹/L, 30-50 × 10⁹/L, and > 50 × 10⁹/L (P = 0.031). Vaccinated patients demonstrated a rapid elevation of PT-IgG, peaking at week 5 post-infection (52.08 IU/mL), while unvaccinated patients showed delayed antibody production, with levels rising significantly only by week 6 (26.99 IU/mL). Although clinical symptoms and complications did not differ significantly between the groups, unvaccinated patients had higher rates of severe indicators.
conclusionVaccination against pertussis accelerates PT-IgG production in infants aged 3-12 months. Unvaccinated patients experience delayed antibody responses, lower PT-IgG levels, and increased risks of severe complications. These findings emphasize the critical role of vaccination in mitigating pertussis-related morbidity.
conclusionTwo-thirds of outpatients were non-adherent to anti-infectives in acute infectious diseases. WHAT IS KNOWN: • Pertussis vaccination influences PT-IgG levels following Bordetella pertussis infection and affects disease severity. WHAT IS NEW: • To our knowledge, this study represents the first large-scale analysis of the impact of pertussis vaccination on antibody kinetic changes during the initial 6 weeks post-Bordetella pertussis infection. • Unvaccinated patients exhibited delayed antibody production and lower peak antibody titers, resulting in a higher probability of severe clinical manifestations. Particular clinical attention should be given to pertussis-unvaccinated patients.
Indexed as
Identifiers
40711589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.